

# Mortality in Parkinson's disease and its association with

Acta Neurologica Scandinavica

110, 118-123

DOI: 10.1111/j.1600-0404.2004.00292.x

Citation Report

#	ARTICLE	IF	CITATIONS
2	Psychiatric aspects of Parkinson's disease. Current Opinion in Psychiatry, 2005, 18, 335-341.	6.3	12
3	Current World Literature. Current Opinion in Psychiatry, 2005, 18, 343-359.	6.3	0
4	Mortality in Parkinson's disease. Acta Neurologica Scandinavica, 2005, 111, 71-71.	2.1	1
6	Prognosis of Parkinson Disease. Archives of Neurology, 2005, 62, 1265.	4.5	198
7	Cognitive, Affective, and Psychiatric Features of Parkinson's Disease. Clinics in Geriatric Medicine, 2006, 22, 773-796.	2.6	30
8	The morphological basis of mental dysfunction in Parkinson's disease. Journal of the Neurological Sciences, 2006, 248, 167-172.	0.6	37
9	Integrating clinical with biobehavioural studies of depression and physical illness. , 0, , 397-408.		5
11	Epidemiology of Parkinson's disease. Lancet Neurology, The, 2006, 5, 525-535.	10.2	3,329
12	Depressive symptom profile in Parkinson's disease: a comparison with depression in elderly patients without Parkinson's disease. International Journal of Geriatric Psychiatry, 2006, 21, 252-258.	2.7	98
13	Prognosis of Parkinson's disease: Time to stage III, IV, V, and to motor fluctuations. Movement Disorders, 2006, 21, 1384-1395.	3.9	126
14	Use of atypical antipsychotics in neurodegenerative diseases. Future Neurology, 2006, 1, 553-562.	0.5	0
16	Depression in patients with Parkinson's disease: identification and treatment. British Journal of Hospital Medicine (London, England: 2005), 2007, 68, 485-488.	0.5	0
17	Estimated life expectancy of Parkinson's patients compared with the UK population. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1304-1309.	1.9	121
18	Treatment of Dementia in Parkinsonian Syndromes with Cholinesterase Inhibitors. Dementia and Geriatric Cognitive Disorders, 2007, 23, 351-367.	1.5	11
19	Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study. , 2007, , 91-104.		66
20	Early-onset Parkinson's disease and depression. Arquivos De Neuro-Psiquiatria, 2007, 65, 5-10.	0.8	15
21	Depression in veterans with Parkinson's disease: frequency, co-morbidity, and healthcare utilization. International Journal of Geriatric Psychiatry, 2007, 22, 543-548.	2.7	26
22	A neuropsychological longitudinal study in Parkinson's patients with and without hallucinations. Movement Disorders, 2007, 22, 2418-2425.	3.9	84

#	ARTICLE	IF	CITATIONS
23	Self-reported depression and antidepressant medication use in essential tremor: cross-sectional and prospective analyses in a population-based study. <i>European Journal of Neurology</i> , 2007, 14, 1138-1146.	3.3	138
24	Mortality in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2007, 115, 367-367.	2.1	0
25	Cerebral amyloid angiopathy in Lewy body disease. <i>Journal of Neural Transmission</i> , 2008, 115, 473-482.	2.8	41
26	Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. <i>Acta Neuropathologica</i> , 2008, 115, 427-436.	7.7	212
27	A validation study of depressive syndromes in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 538-546.	3.9	81
28	Diagnosis and management of Parkinson's disease dementia. <i>International Journal of Clinical Practice</i> , 2008, 62, 1581-1587.	1.7	77
29	Unraveling depression in Parkinson's disease. <i>European Journal of Neurology</i> , 2008, 15, 885-886.	3.3	13
30	Current Management of the Cognitive Dysfunction in Parkinson's Disease: How Far Have We Come?. <i>Experimental Biology and Medicine</i> , 2008, 233, 941-951.	2.4	25
31	Dementia and survival in Parkinson disease. <i>Neurology</i> , 2008, 70, 1017-1022.	1.1	403
32	Parkinson disease and risk of mortality. <i>Neurology</i> , 2008, 70, 1423-1430.	1.1	120
33	Fourteen-year final report of the randomized PDRC-UK trial comparing three initial treatments in PD. <i>Neurology</i> , 2008, 71, 474-480.	1.1	246
34	Receptor-Binding and Pharmacokinetic Properties of Dopaminergic Agonists. <i>Current Topics in Medicinal Chemistry</i> , 2008, 8, 1049-1067.	2.1	56
35	Rivastigmine for the treatment of dementia associated with Parkinson's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2007, Volume 3, 775-783.	2.2	7
36	Neuropsychiatry of Parkinson's disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2009, 67, 930-939.	0.8	35
37	Clinical Features in Early Parkinson Disease and Survival. <i>Archives of Neurology</i> , 2009, 66, 1353-8.	4.5	98
38	Mortality in Parkinson's disease: A 20-year follow-up study. <i>Movement Disorders</i> , 2009, 24, 819-825.	3.9	108
39	Apathy may herald cognitive decline and dementia in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 2391-2397.	3.9	207
40	Parkinson's Disease Dementia. <i>Current Psychiatry Reviews</i> , 2009, 5, 218-225.	0.9	4

#	ARTICLE	IF	CITATIONS
41	Depression in Parkinson's Disease. Canadian Journal of Neurological Sciences, 2010, 37, 61-66.	0.5	31
42	Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurology, 2010, 10, 49.	1.8	90
43	Mitochondrial therapy for Parkinson's disease: Neuroprotective pharmacotherapy may be disease-modifying. Clinical Pharmacology: Advances and Applications, 2010, 2, 185.	1.2	7
44	The estimated life expectancy in a community cohort of Parkinson's disease patients with and without dementia, compared with the UK population. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1093-1098.	1.9	56
45	Factors Affecting Survival of Patients with Neurodegenerative Disease. Neuroepidemiology, 2010, 35, 28-35.	2.3	41
46	Role of Pramipexole in the Management of Parkinson's Disease. CNS Drugs, 2010, 24, 829-841.	5.9	48
47	The cause of death in idiopathic Parkinson's disease. Parkinsonism and Related Disorders, 2010, 16, 434-437.	2.2	109
48	Depression and anxiety related subtypes in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 803-809.	1.9	150
50	Cognitive and psychiatric disturbances in Parkinson's disease. Aging Health, 2011, 7, 123-142.	0.3	6
51	Psychiatric disorders in primary focal dystonia and in Parkinson's disease. Neuropsychiatric Disease and Treatment, 2011, 7, 111.	2.2	7
52	Epidemiology and etiology of Parkinson's disease: a review of the evidence. European Journal of Epidemiology, 2011, 26, 1-58.	5.7	897
53	Diagnostic criteria for depression in Parkinson's disease: A study of symptom patterns using latent class analysis. Movement Disorders, 2011, 26, 2239-2245.	3.9	42
54	Mortality from Parkinson's disease: A population-based prospective study (NEDICES). Movement Disorders, 2011, 26, 2522-2529.	3.9	79
56	Nonmotor problems in Parkinson disease. , 2011, , 183-196.		0
58	The impact of Parkinson's disease as a comorbid diagnosis. Age and Ageing, 2011, 40, 294-296.	1.6	4
59	Ten year survival and outcomes in a prospective cohort of new onset Chinese Parkinson's disease patients. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 607-611.	1.9	151
60	Apathy. American Journal of Alzheimer's Disease and Other Dementias, 2012, 27, 196-201.	1.9	18
61	Predictors of Survival in Patients With Parkinson Disease. Archives of Neurology, 2012, 69, 601.	4.5	130

#	ARTICLE	IF	CITATIONS
63	Drug treatments for the neuropsychiatric complications of Parkinson's disease. Expert Review of Neurotherapeutics, 2012, 12, 1439-1449.	2.8	23
64	Glutamate-based depression GBD. Medical Hypotheses, 2012, 78, 675-681.	1.5	41
65	The Influence of Playing a Non-Reward Game on Motor Ability and Executive Function in Parkinson's Disease. Behavioural Neurology, 2012, 25, 119-125.	2.1	2
66	Depression, Apathy and Anxiety Disorders. Advances in Biological Psychiatry, 2012, , 13-26.	0.2	1
67	Clinical differences among mild cognitive impairment subtypes in Parkinson's disease. Movement Disorders, 2012, 27, 1129-1136.	3.9	87
68	Depression subtypes and 5-year risk of mortality in aged 70 years: a population-based cohort study. International Journal of Geriatric Psychiatry, 2012, 27, 67-75.	2.7	16
69	Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia. Movement Disorders, 2012, 27, 727-734.	3.9	49
70	Catechin attenuates behavioral neurotoxicity induced by 6-OHDA in rats. Pharmacology Biochemistry and Behavior, 2013, 110, 1-7.	2.9	54
71	Depressione e malattia di Parkinson. EMC - Neurologia, 2013, 13, 1-15.	0.0	0
72	Depression in Parkinson's Disease: Identification and Management. Pharmacotherapy, 2013, 33, 972-983.	2.6	35
73	Depression and Parkinson's Disease: Current Knowledge. Current Neurology and Neuroscience Reports, 2013, 13, 409.	4.2	251
74	Apathy in Elderly Nondemented Patients With Parkinson's Disease. Journal of Geriatric Psychiatry and Neurology, 2013, 26, 237-243.	2.3	30
75	Impact of the Parkinson's disease medication protocol program on nurses' knowledge and management of Parkinson's disease medicines in acute and aged care settings. Nurse Education Today, 2013, 33, 458-464.	3.3	16
76	Handbook of Parkinson's Disease. , 2013, , .		14
77	Antidepressants for depression in Parkinson's disease: systematic review and meta-analysis. Journal of Psychopharmacology, 2013, 27, 417-423.	4.0	73
78	Diffusion Tensor Imaging Reveals White Matter Changes Associated With Cognitive Status in Patients With Parkinson's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2013, 28, 154-164.	1.9	60
79	Mini mental Parkinson test: standardization and normative data on an Italian sample. Neurological Sciences, 2013, 34, 1797-1803.	1.9	8
80	Parkinson Hastalarında Cinsel İşlev Bozuklukları ve Kadın ve Erkek Hastalarda Belirleyicileri / Predictors of Sexual Dysfunction in Female and Male Patients with Idiopathic Parkinson's Disease. Dusunen Adam, 2013, , .	0.2	1

#	ARTICLE	IF	CITATIONS
81	Cohort Profile: A population-based cohort to study non-motor symptoms in parkinsonism (EPIPARK). <i>International Journal of Epidemiology</i> , 2013, 42, 128-128k.	1.9	32
82	Neuropsychiatric symptoms in Nigerian patients with Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2013, 128, 9-16.	2.1	14
83	The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1258-1264.	1.9	534
84	DemTect, PANDA, EASY, and MUSIC: Cognitive Screening Tools with Age Correction and Weighting of Subtests According to Their Sensitivity and Specificity. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 813-834.	2.6	32
85	Systematic Review of Traditional Chinese Medicine for Depression in Parkinson's Disease. <i>The American Journal of Chinese Medicine</i> , 2014, 42, 1035-1051.	3.8	42
87	Screening for depression in Parkinson's disease: the performance of two screening questions. <i>Age and Ageing</i> , 2014, 43, 200-205.	1.6	21
88	Treatment of Cognitive, Psychiatric, and Affective Disorders Associated with Parkinson's Disease. <i>Neurotherapeutics</i> , 2014, 11, 78-91.	4.4	62
89	Parkinson's disease and risk of mortality: meta-analysis and systematic review. <i>Acta Neurologica Scandinavica</i> , 2014, 129, 71-79.	2.1	73
90	Survival in Parkinson's disease. Relation with motor and non-motor features. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 613-616.	2.2	62
91	Mortality from Parkinson's disease in China: Findings from a five-year follow up study in Shanghai. <i>Canadian Journal of Neurological Sciences</i> , 2015, 42, 242-247.	0.5	13
92	Structural MRI Correlates of Episodic Memory Processes in Parkinson's Disease Without Mild Cognitive Impairment. <i>Journal of Parkinson's Disease</i> , 2015, 5, 971-981.	2.8	15
93	Cognitive Behaviour Therapy for Depression and Anxiety in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 443-451.	2.8	52
94	Neuroimaging correlates of cognitive impairment and dementia in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 862-870.	2.2	51
95	Prognostic factors for early mortality in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 226-230.	2.2	42
96	Associations between depression and all-cause and cause-specific risk of death: A retrospective cohort study in the Veterans Health Administration. <i>Journal of Psychosomatic Research</i> , 2015, 78, 324-331.	2.6	67
97	Association of depressive symptoms with circadian blood pressure alterations in Parkinson's disease. <i>Journal of Neurology</i> , 2015, 262, 2564-2571.	3.6	17
98	Mortalidade Hospitalar na Doença de Parkinson: Análise Retrospectiva num Hospital Terciário Português. <i>Acta Medica Portuguesa</i> , 2016, 29, 315.	0.4	5
99	Prevalence, impact, and management of depression and anxiety in patients with Parkinson's disease. <i>Journal of Parkinsonism and Restless Legs Syndrome</i> , 2016, , 15.	0.8	3

#	ARTICLE	IF	CITATIONS
100	Management of cognitive impairment in Parkinson's disease. , 0, , 111-121.		0
101	Abnormal Echogenicity of the Substantia Nigra, Raphe Nuclei, and Third-Ventricle Width as Markers of Cognitive Impairment in Parkinsonian Disorders: A Cross-Sectional Study. Parkinson's Disease, 2016, 2016, 1-9.	1.1	3
102	Recent Advance in the Relationship between Excitatory Amino Acid Transporters and Parkinsonâ€™s Disease. Neural Plasticity, 2016, 2016, 1-8.	2.2	39
103	Anxiety and anxious-depression in Parkinson's disease over a 4-year period: a latent transition analysis. Psychological Medicine, 2016, 46, 657-667.	4.5	49
104	The <scp>T</scp>herapeutic <scp>P</scp>otential of <scp>E</scp>xercise to <scp>I</scp>mprove <scp>M</scp>ood, <scp>C</scp>ognition, and S<scp>I</scp>leep in <scp>P</scp>arkinson's <scp>D</scp>isease. Movement Disorders, 2016, 31, 23-38.	3.9	104
105	Factors Related to the 3-year Prognosis of Mobility of Parkinson's Disease Patients. Rigakuryoho Kagaku, 2016, 31, 645-649.	0.1	1
106	Guidelines for dementia or Parkinsonâ€™s disease with depression or anxiety: a systematic review. BMC Neurology, 2016, 16, 244.	1.8	43
107	Management of disease-related behavioral disturbances in Parkinson's disease. , 0, , 127-138.		0
109	Surviving 10Âyears with deep brain stimulation for Parkinson's disease â€“ a followâ€™up of 79 patients. European Journal of Neurology, 2016, 23, 53-61.	3.3	50
110	Sudden unexpected death in Parkinson's disease: Perspectives on what we have learned about sudden unexpected death in epilepsy (SUDEP). Epilepsy and Behavior, 2016, 57, 124-125.	1.7	8
111	The bidirectional longitudinal relationship between insomnia, depression and anxiety in patients with early-stage, medication-naïve Parkinson's disease. Parkinsonism and Related Disorders, 2017, 39, 31-36.	2.2	37
112	A comprehensive overview of the neuropsychiatry of Parkinson's disease: A review. Bulletin of the Menninger Clinic, 2017, 81, 53-105.	0.6	15
113	Cognitive and Neuropsychiatric Features in Parkinson's and Lewy Body Dementias. Archives of Clinical Neuropsychology, 2017, 32, 786-801.	0.5	27
115	Depression and Anxiety in Parkinson's Disease. International Review of Neurobiology, 2017, 133, 623-655.	2.0	107
116	Co-morbidity and polypharmacy in Parkinsonâ€™s disease: insights from a large Scottish primary care database. BMC Neurology, 2017, 17, 126.	1.8	80
117	Neuropsychiatric Predictors of Cognitive Decline in Parkinson Disease: A Longitudinal Study. American Journal of Geriatric Psychiatry, 2017, 25, 279-289.	1.2	38
118	Apolipoprotein Éµ4: A Biomarker for Executive Dysfunction among Parkinson's Disease Patients with Mild Cognitive Impairment. Frontiers in Neuroscience, 2017, 11, 712.	2.8	16
119	Prevalence of depression and receipt of antidepressant pharmacotherapy among patients with Parkinson's disease: a national assessment of US office-based physician visits. Journal of Parkinsonism and Restless Legs Syndrome, 2017, Volume 7, 79-84.	0.8	1

#	ARTICLE	IF	CITATIONS
120	Mortality and quality of death certification in a cohort of patients with Parkinson's disease and matched controls in North Wales, UK at 18 years: a community-based cohort study. <i>BMJ Open</i> , 2018, 8, e018969.	1.9	51
121	The interplay between inflammation, oxidative stress, DNA damage, DNA repair and mitochondrial dysfunction in depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 80, 309-321.	4.8	206
122	Efficacy and tolerability of antidepressants in Parkinson's disease: A systematic review and network meta-analysis. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 642-651.	2.7	43
123	Predictors of Mortality in Nondemented Patients With Parkinson Disease: Motor Symptoms Versus Nonmotor Symptoms. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2018, 31, 19-26.	2.3	25
125	Remote delivery of psychological interventions for Parkinson's disease. <i>International Psychogeriatrics</i> , 2018, 30, 1783-1795.	1.0	76
126	The clinical heterogeneity of Parkinson's disease and its therapeutic implications. <i>European Journal of Neuroscience</i> , 2019, 49, 328-338.	2.6	137
127	Modified Mindfulness-Based Cognitive Therapy for Depressive Symptoms in Parkinson's Disease: a Pilot Trial. <i>Behavioural and Cognitive Psychotherapy</i> , 2019, 47, 446-461.	1.2	27
128	Suicide in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 822-829.	1.9	35
129	Dementia and Parkinson's Disease: Similar and Divergent Challenges in Providing Palliative Care. <i>Frontiers in Neurology</i> , 2019, 10, 54.	2.4	17
130	Long-Term Partnerships in Lewy Body Dementias. , 2019, , .		1
131	Beyond 10 years of levodopa intestinal infusion experience: Analysis of mortality and its predictors. <i>Parkinsonism and Related Disorders</i> , 2020, 76, 98-103.	2.2	11
132	Anxiety: An ignored aspect of Parkinson's disease lacking attention. <i>Biomedicine and Pharmacotherapy</i> , 2020, 131, 110776.	5.6	34
133	Risk factors for depression in patients with Parkinson's disease: A nationwide nested case-control study. <i>PLoS ONE</i> , 2020, 15, e0236443.	2.5	7
134	Biological Sex and Sex Hormone Impacts on Deficits in Episodic-Like Memory in a Rat Model of Early, Pre-motor Stages of Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 942.	2.4	5
135	Palliative Skills for Frontline Clinicians. , 2020, , .		3
136	Exploring Nonmotor Neuropsychiatric Manifestations of Parkinson Disease in a Comprehensive Care Setting. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2021, 34, 181-195.	2.3	3
137	Reinforcement of $\alpha$ -imine-hydroxyl chelation pocket by encapsulating into the $\beta$ -CD cavity for the sterically protective detection of $Al^{3+}$ . <i>Journal of Molecular Liquids</i> , 2021, 323, 114949.	4.9	7
138	Prognostic predictors relevant to end-of-life palliative care in Parkinson's disease and related disorders: a systematic review. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 629-636.	1.9	26



#	ARTICLE	IF	CITATIONS
139	Significance of cerebral amyloid angiopathy and other co-morbidities in Lewy body diseases. Journal of Neural Transmission, 2021, 128, 687-699.	2.8	13
140	Impact of Antidepressants on Cardiac Events and All-Cause Mortality in Parkinson's Disease: A National Data-Linkage Study. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 2499-2510.	2.2	0
141	Mortality of People with Parkinson's Disease in a Large <scp>UK</scp>-Based Cohort Study: Time Trends and Relationship to Disease Duration. Movement Disorders, 2021, 36, 2811-2820.	3.9	8
142	Mild cognitive impairment, dementia and risk of mortality in essential tremor: A longitudinal prospective study of elders. Journal of the Neurological Sciences, 2021, 428, 117563.	0.6	10
143	Fist-Edge-Palm (FEP) test has a high sensitivity in differentiating dementia from normal cognition in Parkinson's disease. Journal of the Neurological Sciences, 2021, 429, 118060.	0.6	0
144	Epidemiology of atypical parkinsonian syndromes. Tzu Chi Medical Journal, 2022, 34, 169.	1.1	5
145	Fearing Parkinson's Disease: Relationships Between Cognition and Emotion. , 2021, , 419-430.		0
147	Parkinson's disease dementia and dementia with lewy bodies.. , 2015, , 227-245.		1
148	Affective Disorders, Psychosis and Dementia in a Community Sample of Older Men with and without Parkinson's Disease. PLoS ONE, 2016, 11, e0163781.	2.5	6
149	The impact of depression on survival of Parkinson's disease patients: a five-year study. Jornal Brasileiro De Psiquiatria, 2013, 62, 8-12.	0.7	5
150	Problem solving therapy for the treatment of depression for a patient with Parkinson's disease and mild cognitive impairment: a case study. Neuropsychiatric Disease and Treatment, 2006, 2, 375-379.	2.2	9
153	Mood Disorders in Parkinson's Disease. Psychiatric Annals, 2020, 50, 95-99.	0.1	2
154	Neuroanatomical changes in Parkinson's disease in relation to cognition: An update. Journal of Advanced Pharmaceutical Technology and Research, 2016, 7, 123.	1.0	31
155	Domperidone, Parkinson disease and sudden cardiac death: Mice and men show the way. Clinics, 2016, 70, 59-61.	1.5	13
156	Depression in Older Patients. , 2006, , 713-725.		1
157	Nonmotor Problems in Parkinson Disease. , 2007, , 193-204.		1
158	Dementia in Parkinson's disease. , 2012, , 368-371.		0
159	Management of psychosis and dementia. , 2013, , 192-224.		1

#	ARTICLE	IF	CITATIONS
160	Management of anxiety and depression. , 2013, , 171-191.		0
162	The Effect of Sleep and Wakefulness Disorders on Cognitive Function in Parkinson's Disease. European Journal of Medicine Series B, 2015, 2, 18-23.	0.0	0
164	Frequency of Cognitive Impairment in Patients with Parkinsonâ€™s Disease. Cureus, 2019, 11, e4733.	0.5	1
165	Parkinsonism and Related Disorders. , 0, , .		0
166	Prognostication and Goals of Care in Advanced Parkinsonâ€™s Disease. , 2020, , 63-71.		0
167	Impaired Curve Negotiation in Drivers with Parkinson's Disease. Turk Noroloji Dergisi = Turkish Journal of Neurology, 2009, 15, 10-18.	0.3	1
168	Mild cognitive impairment in Parkinson's disease. Minerva Medica, 2011, 102, 441-59.	0.9	113
170	What does the Dementia Rating Scale-2 measure? The relationship of neuropsychological measures to DRS-2 total and subscale scores in non-demented individuals with Parkinsonâ€™s disease. Clinical Neuropsychologist, 2023, 37, 174-193.	2.3	2
171	Sudden unexpected death in Parkinson's disease: Insights from clinical practice. Clinics, 2022, 77, 100001.	1.5	5
172	Serotonin Syndrome and Drug Interactions, Hypertensive Complications, and, Adverse Effects of Monoamine Oxidase Inhibitors in Patients with Parkinsonâ€™s Disease. , 2022, , 241-251.		0
175	Frequency of Depressive Disorders in Parkinsonâ€™s Disease: A Systematic Review and Meta-Analysis. Journal of Parkinson's Disease, 2022, 12, 1409-1418.	2.8	8
176	Patients with depression in the early stages of Parkinson's disease: A cross-sectional observational study. Consilium Medicum, 2022, 24, 118-122.	0.3	0
177	Are there morphological differences between Parkinson's disease-dementia and dementia with Lewy bodies?. Parkinsonism and Related Disorders, 2022, 100, 24-32.	2.2	17
178	Morbidity and Associated Factors of Depressive Disorder in Patients With Parkinson's Disease. Journal of Nervous and Mental Disease, 0, Publish Ahead of Print, .	1.0	0
179	Depression in Patients with Parkinsonâ€™s Disease: Current Understanding of its Neurobiology and Implications for Treatment. Drugs and Aging, 2022, 39, 417-439.	2.7	34
180	Physical inactivity is associated with Parkinson's disease mild cognitive impairment and dementia. Mental Health and Physical Activity, 2022, 23, 100461.	1.8	4
181	Review on Î²-cyclodextrin inclusion complex based chemosensors for heavy metals. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2022, 102, 603-618.	1.6	3
183	Comparison of pramipexole and citalopram in the treatment of depression in Parkinson's disease: A randomized parallel-group trial. Journal of Research in Medical Sciences, 2022, 27, 55.	0.9	3

#	ARTICLE	IF	CITATIONS
184	Mortality of Deep Brain Stimulation and Risk Factors in Patients With Parkinson's Disease: A National Cohort Study in Korea. Journal of Korean Medical Science, 2023, 38, .	2.5	1
185	The dilemma between milestones of progression versus clinical scales in Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 169-185.	1.8	0
186	Clinical Significance of Apathy in Parkinson's Disease. European Medical Journal Neurology, 0, , 56-63.	0.0	7
187	The effect of physical exercise on anxiety in people with parkinson's disease: A systematic review of randomized control trials. NeuroRehabilitation, 2023, 52, 387-402.	1.3	2
188	Morphological characteristics differentiate dementia with Lewy bodies from Parkinson disease with and without dementia. Journal of Neural Transmission, 2023, 130, 891-904.	2.8	2
190	Epidemiology of Parkinson's Disease. Advances in Medical Diagnosis, Treatment, and Care, 2023, , 1-12.	0.1	1
191	The Impact of Intestinal Microbiota and Toll-like Receptor 2 Signaling on $\alpha$ -Synuclein Pathology in Nontransgenic Mice Injected with $\alpha$ -Synuclein Preformed Fibrils. Microorganisms, 2024, 12, 106.	3.6	0
192	The impact of psychiatric comorbidity on Parkinson's disease outcomes: a systematic review and meta-analysis. Lancet Regional Health - Europe, The, 2024, 39, 100870.	5.6	0